Suppr超能文献

[大血管冠状动脉疾病患者的糖尿病筛查:新的欧洲指南是在倒退吗?]

[Diabetes Screening in Patients with Macrovascular Coronary Disease: Are the New European Guidelines a Step Backwards?].

作者信息

Ribeiro Andreia, Baptista Sérgio Bravo, Faustino Mariana, Alves Paulo, Abreu Pedro Farto, Gil Victor Machado, Morais Carlos

机构信息

Faculdade de Medicina. Universidade de Lisboa. Lisboa. Portugal.

Serviço de Cardiologia. Hospital Fernando Fonseca. Amadora. Portugal.

出版信息

Acta Med Port. 2017 Jun 30;30(6):434-442. doi: 10.20344/amp.7990.

Abstract

BACKGROUND

The new European guidelines on diabetes mellitus and cardiovascular diseases propose that the FINnish Diabetes RIsk SCore should be used to evaluate the risk of diabetes mellitus and that diabetes mellitus screening in coronary artery disease patients should be based on fasting glucose and HbA1c. The 2 hour oral glucose tolerance test, recommended for all pts in the previous guidelines, is now only recommended for 'inconclusive' cases. We aimed to evaluate this new strategy.

MATERIAL AND METHODS

Fasting glucose, HbA1c and glucose tolerance test (75 g, 2h) were prospectively evaluated in a consecutive group of pts with coronary artery disease. ADA criteria (both glucose tolerance test and HbA1c) were used to define diabetes mellitus and pre-diabetes mellitus. Diabetes mellitus risk was evaluated according to the FINnish Diabetes RIsk SCore.

RESULTS

A total of 135 patients were included (mean age 62.3 +/- 13.1 years, 99 males). Glucose tolerance test and HbA1c together diagnosed 18 (13.3%) new cases of diabetes mellitus and 77 (57.0%) patients with pre-diabetes mellitus. Fasting glucose + HbA1c (guidelines strategy) identified 12/18 patients with diabetes mellitus (Sens 66.7%; negative predictive value 95.1%; Kappa 0.78; p < 0.0001) and 83/95 patients with glucose anomalies (pre- diabetes mellitus + diabetes mellitus) (Sens 87.4%; negative predictive value 76.9%). Performing glucose tolerance test in the 29 patients with an elevated FINnish Diabetes RIsk SCore would allow identifying 15/18 patients with diabetes mellitus (Sens 83.3%; negative predictive value 97.5%; Kappa 0.85; p < 0.0001) and 86/95 patients with glucose anomalies (Sens 90.5%; negative predictive value 81.6%).

DISCUSSION

Although this strategy improved the screening accuracy, one in each six patients with diabetes mellitus would still remain undiagnosed, as compared to measuring HbA1c and performing an glucose tolerance test in all patients.

CONCLUSION

Using the FINnish Diabetes RIsk SCore to select candidates to additional glucose tolerance test improves the accuracy for identifying diabetic patients, as compared with fasting glucose + HbA1c alone. However, 1/6 patients diabetes mellitus is still left undiagnosed with this strategy proposed by the current guidelines.

摘要

背景

欧洲关于糖尿病和心血管疾病的新指南建议使用芬兰糖尿病风险评分来评估糖尿病风险,并且冠状动脉疾病患者的糖尿病筛查应基于空腹血糖和糖化血红蛋白。之前指南推荐所有患者进行的2小时口服葡萄糖耐量试验,现在仅推荐用于“不确定”的病例。我们旨在评估这一新策略。

材料与方法

对一组连续的冠状动脉疾病患者前瞻性地评估空腹血糖、糖化血红蛋白和葡萄糖耐量试验(75克,2小时)。采用美国糖尿病协会标准(葡萄糖耐量试验和糖化血红蛋白两者)来定义糖尿病和糖尿病前期。根据芬兰糖尿病风险评分评估糖尿病风险。

结果

共纳入135例患者(平均年龄62.3±13.1岁,男性99例)。葡萄糖耐量试验和糖化血红蛋白共同诊断出18例(13.3%)新糖尿病病例和77例(57.0%)糖尿病前期患者。空腹血糖+糖化血红蛋白(指南策略)识别出12/18例糖尿病患者(灵敏度66.7%;阴性预测值95.1%;Kappa值0.78;p<0.0001)和83/95例血糖异常患者(糖尿病前期+糖尿病)(灵敏度87.4%;阴性预测值76.9%)。对芬兰糖尿病风险评分升高的29例患者进行葡萄糖耐量试验可识别出15/18例糖尿病患者(灵敏度83.3%;阴性预测值97.5%;Kappa值0.85;p<0.0001)和86/95例血糖异常患者(灵敏度90.5%;阴性预测值81.6%)。

讨论

尽管该策略提高了筛查准确性,但与对所有患者测量糖化血红蛋白并进行葡萄糖耐量试验相比,每六例糖尿病患者中仍有一例未被诊断出来。

结论

与单独使用空腹血糖+糖化血红蛋白相比,使用芬兰糖尿病风险评分来选择进行额外葡萄糖耐量试验的对象可提高识别糖尿病患者的准确性。然而,按照当前指南提出的这一策略,仍有1/6的糖尿病患者未被诊断出来。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验